{"id":65765,"date":"2026-05-20T12:17:09","date_gmt":"2026-05-20T04:17:09","guid":{"rendered":"https:\/\/flcube.com\/?p=65765"},"modified":"2026-05-20T12:17:10","modified_gmt":"2026-05-20T04:17:10","slug":"immuneonco-doses-first-patient-in-phase-ii-trial-of-imm0306-for-systemic-lupus-erythematosus","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65765","title":{"rendered":"ImmuneOnco Doses First Patient in Phase II Trial of IMM0306 for Systemic Lupus Erythematosus"},"content":{"rendered":"\n<p><strong>ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1541:HKG\">HKG: 1541<\/a>) announced today the dosing of the first patient in its <strong>Phase II clinical study<\/strong> evaluating <strong>IMM0306<\/strong>, a <strong>bispecific antibody (BsAb)<\/strong> targeting <strong>CD47 and CD20<\/strong>, for the treatment of <strong>systemic lupus erythematosus (SLE)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-design\">Clinical Trial Design<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Phase<\/strong><\/td><td>II<\/td><\/tr><tr><td><strong>Design<\/strong><\/td><td>Randomized, placebo-controlled<\/td><\/tr><tr><td><strong>Patient Enrollment<\/strong><\/td><td>Approximately 90 patients<\/td><\/tr><tr><td><strong>Randomization Ratio<\/strong><\/td><td>1:1:1<\/td><\/tr><tr><td><strong>Treatment Arms<\/strong><\/td><td>IMM0306 (1.2 mg\/kg), IMM0306 (1.6 mg\/kg), Placebo<\/td><\/tr><tr><td><strong>Primary Indication<\/strong><\/td><td>Systemic lupus erythematosus (SLE)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Bispecific antibody (BsAb) targeting CD47 and CD20 pathways simultaneously<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Novel dual-target approach designed to modulate multiple immune pathways involved in SLE pathogenesis<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Currently in Phase II for SLE; also under investigation for IgG4-related disease (IgG4-RD) and primary Sj\u00f6gren&#8217;s syndrome (pSS)<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Proprietary bispecific platform owned by ImmuneOnco<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-pipeline\">Clinical Development Pipeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Development Stage<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Systemic Lupus Erythematosus (SLE)<\/strong><\/td><td>Phase II<\/td><td>First patient dosed<\/td><\/tr><tr><td><strong>IgG4-Related Disease (IgG4-RD)<\/strong><\/td><td>Clinical studies<\/td><td>Ongoing<\/td><\/tr><tr><td><strong>Primary Sj\u00f6gren&#8217;s Syndrome (pSS)<\/strong><\/td><td>Clinical studies<\/td><td>Ongoing<\/td><\/tr><tr><td><strong>Other Autoimmune Conditions<\/strong><\/td><td>Preclinical\/Exploratory<\/td><td>In development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The company believes that IMM0306&#8217;s dual-target mechanism may offer advantages over single-target approaches by simultaneously addressing multiple aspects of the dysregulated immune response characteristic of SLE and related autoimmune disorders.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SLE Treatment Landscape:<\/strong> Current therapies often involve broad immunosuppression with significant side effects; targeted biologics represent a growing segment with unmet needs<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> IMM0306&#8217;s bispecific design differentiates it from existing CD20-only or CD47-only approaches in development<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> The global SLE therapeutics market is projected to reach $3.5 billion by 2028, with biologics capturing an increasing share<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Successful Phase II data would support advancement to pivotal Phase III studies, potentially enabling accelerated approval pathways in major markets<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, trial design, and potential therapeutic benefits of IMM0306. Actual results may differ materially due to risks inherent in clinical drug development, including enrollment challenges, safety findings, and efficacy outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051901274_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026051901274_c.\"><\/object><a id=\"wp-block-file--media-978dc91b-18d0-447b-b262-58e13e33ff44\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051901274_c.pdf\">2026051901274_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051901274_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-978dc91b-18d0-447b-b262-58e13e33ff44\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) announced today the dosing of the first patient&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,1028,229],"class_list":["post-65765","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-1541","tag-immuneonco-biopharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>ImmuneOnco Doses First Patient in Phase II Trial of IMM0306 for Systemic Lupus Erythematosus - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) announced today the dosing of the first patient in its Phase II clinical study evaluating IMM0306, a bispecific antibody (BsAb) targeting CD47 and CD20, for the treatment of systemic lupus erythematosus (SLE).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65765\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmuneOnco Doses First Patient in Phase II Trial of IMM0306 for Systemic Lupus Erythematosus\" \/>\n<meta property=\"og:description\" content=\"ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) announced today the dosing of the first patient in its Phase II clinical study evaluating IMM0306, a bispecific antibody (BsAb) targeting CD47 and CD20, for the treatment of systemic lupus erythematosus (SLE).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65765\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-20T04:17:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-20T04:17:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65765#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65765\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"ImmuneOnco Doses First Patient in Phase II Trial of IMM0306 for Systemic Lupus Erythematosus\",\"datePublished\":\"2026-05-20T04:17:09+00:00\",\"dateModified\":\"2026-05-20T04:17:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65765\"},\"wordCount\":349,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 1541\",\"ImmuneOnco Biopharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65765#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65765\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65765\",\"name\":\"ImmuneOnco Doses First Patient in Phase II Trial of IMM0306 for Systemic Lupus Erythematosus - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-20T04:17:09+00:00\",\"dateModified\":\"2026-05-20T04:17:10+00:00\",\"description\":\"ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) announced today the dosing of the first patient in its Phase II clinical study evaluating IMM0306, a bispecific antibody (BsAb) targeting CD47 and CD20, for the treatment of systemic lupus erythematosus (SLE).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65765#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65765\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65765#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmuneOnco Doses First Patient in Phase II Trial of IMM0306 for Systemic Lupus Erythematosus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ImmuneOnco Doses First Patient in Phase II Trial of IMM0306 for Systemic Lupus Erythematosus - Insight, China&#039;s Pharmaceutical Industry","description":"ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) announced today the dosing of the first patient in its Phase II clinical study evaluating IMM0306, a bispecific antibody (BsAb) targeting CD47 and CD20, for the treatment of systemic lupus erythematosus (SLE).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65765","og_locale":"en_US","og_type":"article","og_title":"ImmuneOnco Doses First Patient in Phase II Trial of IMM0306 for Systemic Lupus Erythematosus","og_description":"ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) announced today the dosing of the first patient in its Phase II clinical study evaluating IMM0306, a bispecific antibody (BsAb) targeting CD47 and CD20, for the treatment of systemic lupus erythematosus (SLE).","og_url":"https:\/\/flcube.com\/?p=65765","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-20T04:17:09+00:00","article_modified_time":"2026-05-20T04:17:10+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65765#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65765"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"ImmuneOnco Doses First Patient in Phase II Trial of IMM0306 for Systemic Lupus Erythematosus","datePublished":"2026-05-20T04:17:09+00:00","dateModified":"2026-05-20T04:17:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65765"},"wordCount":349,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","HKG: 1541","ImmuneOnco Biopharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65765#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65765","url":"https:\/\/flcube.com\/?p=65765","name":"ImmuneOnco Doses First Patient in Phase II Trial of IMM0306 for Systemic Lupus Erythematosus - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-20T04:17:09+00:00","dateModified":"2026-05-20T04:17:10+00:00","description":"ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) announced today the dosing of the first patient in its Phase II clinical study evaluating IMM0306, a bispecific antibody (BsAb) targeting CD47 and CD20, for the treatment of systemic lupus erythematosus (SLE).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65765#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65765"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65765#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"ImmuneOnco Doses First Patient in Phase II Trial of IMM0306 for Systemic Lupus Erythematosus"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65765"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65765\/revisions"}],"predecessor-version":[{"id":65768,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65765\/revisions\/65768"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}